Bildgebung genetischer Aspekte des Parkinson-Syndroms

  • Kathrin Reetz
Conference paper

Zusammenfassung

Die Zahl der mit dem Parkinson-Syndrom identifizierten krankheitsassoziierten Gene ist seit der Erstentdeckung im Jahre 1997 stetig – auf nunmehr insgesamt 18 Genorte – angestiegen (PARK1-18). Dies erlaubt einen tieferen Einblick in die zugrunde liegenden pathophysiologischen Grundlagen. Träger der krankheitsassoziierten Gene bieten uns die einzigartige Gelegenheit, auch die präsymptomatische Phase dieser neurodegenerativen Erkrankung zu untersuchen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bekris LM, Mata IF, Zabetian CP (2010) The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 23:228–42PubMedCrossRefGoogle Scholar
  2. Binkofski F, Reetz K, Gaser C, Hilker R, Hagenah J, Hedrich K et al. (2007) Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia. Neurology 69:842–50PubMedCrossRefGoogle Scholar
  3. Braak H, Del Tredici K (2008) Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 70:1916–25PubMedCrossRefGoogle Scholar
  4. Buhmann C, Binkofski F, Klein C, Buchel C, van Eimeren T, Erdmann C et al. (2005) Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. Brain 128(Pt 10):2281–90PubMedCrossRefGoogle Scholar
  5. Farrer MJ (2006) Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 7:306–18PubMedCrossRefGoogle Scholar
  6. Hilker R, Klein C, Hedrich K, Ozelius LJ, Vieregge P, Herholz K et al. (2002) The striatal dopaminergic deficit is dependent on the number of mutant alleles in a family with mutations in the parkin gene: evidence for enzymatic parkin function in humans. Neurosci Lett 323:50–4PubMedCrossRefGoogle Scholar
  7. Khan NL, Brooks DJ, Pavese N, Sweeney MG, Wood NW, Lees AJ et al. (2002a) Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 125:2248–56CrossRefGoogle Scholar
  8. Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ et al. (2002b) Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 52:849–53CrossRefGoogle Scholar
  9. Klein C, Schlossmacher MG (2006) The genetics of Parkinson disease: Implications for neurological care. Nat Clin Pract Neurol 2:136–46PubMedCrossRefGoogle Scholar
  10. Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A et al. (2003) Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet 12:2599–608PubMedCrossRefGoogle Scholar
  11. Reetz K, Lencer R, Steinlechner S, Gaser C, Hagenah J, Buchel C et al. (2008) Limbic and Frontal Cortical Degeneration Is Associated with Psychiatric Symptoms in PINK1 Mutation Carriers. Biol Psychiatry 64(3):241–7PubMedCrossRefGoogle Scholar
  12. Reetz K, Tadic V, Kasten M, Bruggemann N, Schmidt A, Hagenah J et al. (2010) Structural imaging in the presymptomatic stage of genetically determined parkinsonism. Neurobiol Dis 39:402–8PubMedCrossRefGoogle Scholar
  13. Steinlechner S, Stahlberg J, Volkel B, Djarmati A, Hagenah J, Hiller A et al. (2007) Co-occurrence of affective and schizophrenia spectrum disorders with PINK1 mutations. J Neurol Neurosurg Psychiatry 78:532–5PubMedCrossRefGoogle Scholar
  14. Vegt JP van der, van Nuenen BF, Bloem BR, Klein C, Siebner HR (2009) Imaging the impact of genes on Parkinson's disease. Neuroscience 164(1):191–204PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Kathrin Reetz
    • 1
  1. 1.Neurologische KlinikUniversitätsklinikum AachenAachen

Personalised recommendations